ScreenerHero

AYTUAytu Biopharma, Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · aytubio.com
2.370USD+0.42%Mkt Cap: 25.44M $P/E: —

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hype…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap25.44M $
Enterprise Value20.69M $
Revenue (TTM)56.60M $
Gross Profit45.83M $
Net Income (TTM)-13.56M $
Revenue/Share6.158 USD
Last Price2.370 USD
Fiscal Year EndJun 2025
MR QuarterMar 2026
Employees82
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINUS0547548588
Valuation
P/E (Trailing)—
P/E (Forward)-30.40
PEG—
EV/EBITDA-7.88
EV/Revenue0.37
P/S0.43
P/B0.70
EPS (TTM)-4.48
EPS (Forward)-0.07
52W Range
1.65051% of range3.070
52W High3.070 USD
52W Low1.650 USD
Profitability
Gross Margin69.04%
Oper. Margin-32.74%
EBITDA Margin-4.64%
Profit Margin-20.43%
ROE-71.51%
ROA-10.92%
Growth
Revenue Growth-32.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.94M $
CapEx (TTM)3.23M $
FCF Margin-2.11%
FCF Yield-4.69%
Net Debt-3.78M $
Net Debt/EBITDA1.44
Balance Sheet
Debt/Equity1.15
Current Ratio1.12
Quick Ratio0.85
Book Value/Sh3.274 USD
Cash/Share2.489 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateDec 9, 2020
Splits
Last Split1:20
Split DateJan 6, 2023
Analyst Consensus
Rating—
Target (Mean)9.500 USD
Upside (mean)+300.8%
Target Range7.000 USD – 14.50 USD
$7.000+300.8% to mean$14.50
# Analysts3
Ownership
Shares Out.10.73M
Float7.38M
Insiders10.10%
Institutions35.96%
Short Interest
Short Ratio12.4d
Short % Float3.54%
Short % Out.3.04%
Shares Short326.23K
Short (prev mo.)348.50K
Technical
SMA 502.221 (+6.7%)
SMA 2002.373 (-0.1%)
Beta0.26
S&P 52W Chg18.16%
Avg Vol (30d)27.75K
Avg Vol (10d)34.79K
Technical Indicators
RSI (14)59.3
MACD0.0487
MACD Signal0.0395
MACD Hist.+0.0092
BB Upper2.488 USD
BB Middle2.267 USD
BB Lower2.045 USD
BB Width19.53%
ATR (14)0.0878 USD
Vol Ratio (20d)1.66x